Advances in the treatment of non-small cell lung cancer: focus on anti-PD-1/PD-L1 antibody / 中国医师杂志
Journal of Chinese Physician
;
(12): 1275-1278, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-610810
ABSTRACT
Immunotherapy is revolutionizing the treatment of non-small cell lung cancer (NSCLC).Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies have recently led to significant and durable improvements in the clinical outcome of NSCLC,and the anti-PD-1 antibody has been approved to use in first-line and second-line treatment of NSCLC.However,there are still many problems to be solved.The role of PD-L1 as a predictive biomarker remains unclear.Combination treatment models are being explored.This review summarizes the clinical efficacy,drug adverse reaction,combined treatment,and potential immune biomarkers of anti-PD-1/PD-L1 antibody research progress in the treatment of NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Journal of Chinese Physician
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS